Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 7, Issue 3-4, Pages 166-170Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1399-3062.2005.00112.x
Keywords
cytornegalovirus; resistance; ganciclovir; valganciclovir; solid organ transplantation
Categories
Ask authors/readers for more resources
Clinical consequences of ganciclovir resistant cytomegalovirus (CMV) infections were studied during 2 large prophylactic trials consisting of 100 days of valganciclovir or ganciclovir prophylaxis in solid organ transplant (SOT) recipients. The first one involved 301 high-risk (CMV donor seropositive/ recipient seronegative) SOT recipients excluding lung transplants followed for 12 months, whereas the second one involved 80 lung transplant patients evaluated over 6 months. Among the 7 patients (4 non-lung and 3 lung transplant patients) carrying viruses with known ganciclovir resistance mutations in blood, adverse clinical outcome was only observed in the lung transplant recipients. Additionally, no CMV resistance mutations were observed in non-lung transplant patients receiving valcanciclovir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available